This trial is active, not recruiting.

Condition major depressive disorder
Treatment glyx-13 10 mg/kg
Phase phase 2
Sponsor Naurex, Inc
Start date February 2015
End date December 2017
Trial size 61 participants
Trial identifier NCT02192099, GLYX13-C-203


Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
IV Dose of GLYX-13
glyx-13 10 mg/kg GLYX-13 IV Dose
Intravenous administration of 10 mg/kg into arm. Can be adjusted to 5 mg/kg weekly or biweekly.

Primary Outcomes

Adverse events
time frame: 36 months

Secondary Outcomes

Change in HDRS-17 to end of participation
time frame: 36 months

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1. Participants who have completed 8 weeks of treatment in the preceding study (GLYX13-C-202, NCT01684163. 2. Participants who wish to continue treatment with GLYX-13 after the preceding study. 3. Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD). 4. Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal. 5. Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor. 6. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments. 7. Based on the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes (MDEs) are permitted. Exclusion Criteria: 1. Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD. 2. A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder 3. Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis. 4. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes. 5. Currently hospitalized or residing in an in-patient facility during study participation. 6. Substance abuse since the end of participation in GLYX13-C-202, including greater than or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator 7. Women who are planning to become pregnant during the course of the study. 8. Allergy or intolerance to current antidepressant or other current medications. 9. Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial with the exception of GLYX13-C-202. 10. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused 11. Pose current (past 6 months) suicide risk based on administration of the C SSRS and the investigator's clinical judgment. 12. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease.

Additional Information

Official title Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Description Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202 in an open label extension trial.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Naurex, Inc.